Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...

Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics ...

The panel reviews the mechanisms, efficacy, and tolerability of novel treatments, including perfluorohexyloctane (Miebo), ...

Health Canada approved Eydenzelt, a biosimilar of Eylea, for multiple ophthalmic indications, based on comprehensive evidence ...

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which ...

PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...

LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted a New Drug Application (NDA) to the Ministry of Food ...